<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Maribavir: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Maribavir: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Maribavir: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="134463" href="/d/html/134463.html" rel="external">see "Maribavir: Drug information"</a> and <a class="drug drug_patient" data-topicid="134575" href="/d/html/134575.html" rel="external">see "Maribavir: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F56410669"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Livtencity</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57576164"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Livtencity</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F56399576"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antiviral Agent</span></li></ul></div>
<div class="block dop drugH1Div" id="F56418143"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="39f1729d-618f-4fc6-b162-ef93f4b98b4f">Cytomegalovirus, refractory, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, refractory, treatment; posttransplant: </b>Children ≥12 years and Adolescents weighing ≥35 kg: Oral: 400 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F56418144"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild, moderate, or severe impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">End-stage renal disease, including patients on dialysis: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F56418145"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥12 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild or moderate impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied).</p></div>
<div class="block doa drugH1Div" id="F56416219"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="134463" href="/d/html/134463.html" rel="external">see "Maribavir: Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="39f1729d-618f-4fc6-b162-ef93f4b98b4f">Cytomegalovirus, refractory, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cytomegalovirus, refractory, treatment (posttransplant): Oral:</b> 400 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34864943']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34864943'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F56416221"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild, moderate, or severe impairment: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">End-stage renal disease, including patients on dialysis: There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block doha drugH1Div" id="F56416222"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild or moderate impairment (Child-Pugh class A or B): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block adr drugH1Div" id="F56407918"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Reported adverse reactions are for adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (19%), nausea (21%), vomiting (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased hemoglobin (1% to 32%), decreased platelet count (5% to 18%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Infection (23%; including cytomegalovirus disease)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Fatigue (12%), taste disorder (46%)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine (7% to 33%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%: Hematologic &amp; oncologic: Decreased neutrophils (2% to 4%)</p></div>
<div class="block coi drugH1Div" id="F56396737"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">There are no contraindications listed in the manufacturer's US labeling.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">
<i>Canadian labeling:</i> Hypersensitivity to maribavir or any component of the formulation; coadministration with ganciclovir or valganciclovir.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:0em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F56416208"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Virologic failure/relapse: Virologic failure due to resistance may occur during and after treatment with maribavir. Virologic relapse posttreatment usually occurs within 4 to 8 weeks after maribavir discontinuation. Some maribavir pUL97 resistance-associated substitutions confer cross-resistance to ganciclovir and valganciclovir. If a patient is not responding to treatment or relapses, check for maribavir resistance.</p></div>
<div class="block foc drugH1Div" id="F56410670"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Livtencity: 200 mg [contains fd&amp;c blue #1 (brilliant blue)]</p></div>
<div class="block geq drugH1Div" id="F56410668"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F56445033"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Livtencity Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $266.78</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57576165"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Livtencity: 200 mg [contains fd&amp;c blue #1 (brilliant blue)]</p></div>
<div class="block admp drugH1Div" id="F56418146"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer without regard to food; may administer whole, crushed, or dispersed.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Dispersed or crushed tablet if unable to swallow whole tablet</i>: Add appropriate number of tablets to a suitable container; tablets may be crushed or allowed to disperse without crushing; add 30 mL of drinking water for every 400 mg of drug. Swirl container to mix and administer before drug particles settle. Rinse container with 15 mL of drinking water and administer; if drug particles remain in the container repeat container rinse with 15 mL of water and administer.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Orogastric (OG) or nasogastric (NG) administration of dispersed tablet</i>: Using a 50 to 60 mL OG/NG compatible catheter-tipped syringe, remove the plunger, place 400 mg dose (two 200 mg tablets) in syringe, and put plunger back in place. Draw up 30 mL of drinking water into syringe and pull back plunger further to allow air space in the syringe. Cap syringe and shake syringe well for 30 to 45 seconds until tablets disperse completely; administer. Draw up 15 mL drinking water into the syringe and flush the OG/NG tube; repeat 15 mL flush at least one time, and a second time if any drug particles remain in syringe. If dose &gt;400 mg, repeat all steps for each 400 mg dose increment.</p></div>
<div class="block adm drugH1Div" id="F56416223"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b> Administer with or without food. Tablet may be taken whole, dispersed, or crushed to administer by mouth, or dispersed through an NG or orogastric (OG) tube (≥10 French).</p>
<p style="text-indent:-2em;margin-left:2em;">For patients unable to swallow tablets whole, may administer as an oral suspension. Place tablets for prescribed dose in a container and add appropriate volume of drinking water to make a suspension; do not use other liquids. Tablets may also be crushed with a spoon prior to adding water. Swirl container gently to keep particles from settling prior to administration; the mixture will have a bitter taste. After administering the initial suspension, rinse container with 15 mL of drinking water and administer contents; visually inspect container and repeat rinsing of container if particles remain. Oral suspension may be prepared and stored at room temperature for up to 8 hours.</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:center;">
<b>Number of Maribavir Tablets and Volume of Drinking Water Needed to Make Suspension for Oral Administration of Dispersed or Crushed Tablets</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" valign="middle">
<p style="text-indent:0em;">Recommended dosage (mg)</p></th>
<th align="center">
<p style="text-indent:0em;">Number of 200 mg tablets</p></th>
<th align="center">
<p style="text-indent:0em;">Volume of drinking water (mL)</p></th></tr></thead>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">400</p></td>
<td align="center">
<p style="text-indent:0em;">2</p></td>
<td align="center">
<p style="text-indent:0em;">30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">800</p></td>
<td align="center">
<p style="text-indent:0em;">4</p></td>
<td align="center">
<p style="text-indent:0em;">60</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">1,200</p></td>
<td align="center">
<p style="text-indent:0em;">6</p></td>
<td align="center">
<p style="text-indent:0em;">90</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">NG or OG feeding tube (≥10 French): Place a maximum of 2 tablets (400 mg total) into a 50 or 60 mL catheter-tip compatible syringe. Draw 30 mL of drinking water (do not use other liquids) into syringe and hold syringe with tip pointing upward; pull plunger to a higher volume position (for air space in syringe), return cap on syringe (if applicable), and shake well for ~30 to 45 seconds or until tablets are completely dispersed. Once the tablets are completely dispersed in syringe, attach syringe to the NG or OG tube and administer the dispersion before it settles. Flush with 15 mL of water in the same syringe and NG or OG tube; visually inspect syringe and repeat flushing of NG or OG tube if particles remain. For doses of 800 mg or 1,200 mg, repeat until full dose is administered; same syringe, NG or OG tube may be used. Oral suspension may be prepared and stored at room temperature for up to 8 hours.</p></div>
<div class="block hazard drugH1Div" id="F57241039"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">This medication is not on the NIOSH (2016) list; however, it may meet the criteria for a hazardous drug. Maribavir may cause teratogenicity and reproductive toxicity.</p>
<p style="text-indent:-2em;margin-left:2em;">Use appropriate precautions for receiving, handling, storage, preparation, dispensing, transporting, administration, and disposal. Follow NIOSH and USP 800 recommendations <b>and</b> institution-specific policies/procedures for appropriate containment strategy (NIOSH 2016; USP-NF 2020).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Facilities may perform risk assessment of some hazardous drugs to determine if appropriate for alternative handling and containment strategies (USP-NF 2020). Refer to institution-specific handling policies/procedures.</p></div>
<div class="block sts drugH1Div" id="F56416210"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); brief exposure to 15°C to 30°C (59°F to 86°F) permitted. Prepared suspension may be stored at room temperature for up to 8 hours.</p></div>
<div class="block usep drugH1Div" id="F56398371"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of posttransplant cytomegalovirus (CMV) infection/disease that is refractory to treatment (with or without genotypic resistance) with ganciclovir, valganciclovir, cidofovir, or foscarnet (FDA approved in pediatric patients ≥12 years of age weighing ≥35 kg and adults).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>Note</b>: Approval in pediatric patients is based on likelihood of similar exposures (determined via modeling/simulation); has not been studied in patients &lt;18 years of age.</p></div>
<div class="block cyt drugH1Div" id="F56425462"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP1A2 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F56425459"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Maribavir. Management: Increase the dose of maribavir to 800 mg twice daily when combined with carbamazepine.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Maribavir may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Maribavir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Maribavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Maribavir may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Everolimus: Maribavir may increase the serum concentration of Everolimus. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: May decrease the serum concentration of Maribavir. Management: Increase the dose of maribavir to 1,200 mg twice daily with concomitant use of fosphenytoin or phenytoin.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ganciclovir-Valganciclovir: Maribavir may diminish the therapeutic effect of Ganciclovir-Valganciclovir. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">PHENobarbital: May decrease the serum concentration of Maribavir. Management: Increase the dose of maribavir to 1,200 mg twice daily with concomitant use of phenobarbital.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Primidone: May decrease the serum concentration of Maribavir. Management: Increase the dose of maribavir to 1,200 mg twice daily with concomitant use of primidone.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifabutin: May decrease the serum concentration of Maribavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: Maribavir may increase the serum concentration of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sirolimus Products: Maribavir may increase the serum concentration of Sirolimus Products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Maribavir.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Maribavir may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56416205"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">In initial studies, patients who could become pregnant were required to have a negative pregnancy test prior to treatment and use effective contraception during therapy (Maertens 2019; Papanicolaou 2019).</p></div>
<div class="block pri drugH1Div" id="F56416206"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Based on ex vivo human placenta perfusion studies, maribavir is expected to cross the placenta (Faure Bardon 2020).</p>
<p style="text-indent:0em;margin-top:2em;">Adverse events were observed in some animal reproduction studies at doses lower than the equivalent recommended human dose. Pregnant patients were excluded from initial studies (Maertens 2019; Papanicolaou 2019).</p></div>
<div class="block mopp drugH1Div" id="F56418147"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Cytomegalovirus DNA levels as clinically appropriate; assess for resistance (ie, maribavir pUL97 resistance substitutions) in patients not responding to treatment.</p></div>
<div class="block pha drugH1Div" id="F56416211"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Maribavir is a benzimidazole riboside antiviral that competitively inhibits the protein kinase activity of human cytomegalovirus enzyme pUL97, resulting in inhibition of the phosphorylation of proteins.</p></div>
<div class="block phk drugH1Div" id="F56416212"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>ss</sub>: 27.3 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic via CYP3A4 (major) and CYP1A2 (minor) to inactive metabolites.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Transplant recipients: 4.32 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak: 1 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (61% [&lt;2% unchanged]); feces (14% [5.7% unchanged]).</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs–Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 43-NF 38). Rockville, MD: United States Pharmacopeia Convention; 2020:74-92.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34864943">
<a name="34864943"></a>Avery RK, Alain S, Alexander BD, et al; SOLSTICE Trial Investigators. Maribavir for refractory cytomegalovirus infections with or without resistance post-transplant: results from a phase 3 randomized clinical trial. <i>Clin Infect Dis</i>. 2022;75(4):690-701. doi:10.1093/cid/ciab988<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/maribavir-pediatric-drug-information/abstract-text/34864943/pubmed" id="34864943" target="_blank">34864943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32353010">
<a name="32353010"></a>Faure Bardon V, Peytavin G, Lê MP, et al. Placental transfer of Letermovir &amp; Maribavir in the ex vivo human cotyledon perfusion model. New perspectives for in utero treatment of congenital cytomegalovirus infection. <i>PLoS One</i>. 2020;15(4):e0232140. doi:10.1371/journal.pone.0232140<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/maribavir-pediatric-drug-information/abstract-text/32353010/pubmed" id="32353010" target="_blank">32353010</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Livtencity.1">
<a name="Livtencity.1"></a>Livtencity (maribavir) [prescribing information]. Lexington, MA: Takeda Pharmaceuticals America Inc; April 2023.</div>
</li>
<li>
<div class="reference">
                  Livtencity (maribavir) [product monograph]. Toronto, Ontario, Canada: Takeda Canada Inc; September 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31532960">
<a name="31532960"></a>Maertens J, Cordonnier C, Jaksch P, et al. Maribavir for preemptive treatment of cytomegalovirus reactivation. <i>N Engl J Med</i>. 2019;381(12):1136-1147. doi:10.1056/NEJMoa1714656<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/maribavir-pediatric-drug-information/abstract-text/31532960/pubmed" id="31532960" target="_blank">31532960</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30329038">
<a name="30329038"></a>Papanicolaou GA, Silveira FP, Langston AA, et al. Maribavir for refractory or resistant cytomegalovirus infections in hematopoietic-cell or solid-organ transplant recipients: a randomized, dose-ranging, double-blind, phase 2 study. <i>Clin Infect Dis</i>. 2019;68(8):1255-1264. doi:10.1093/cid/ciy706<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/maribavir-pediatric-drug-information/abstract-text/30329038/pubmed" id="30329038" target="_blank">30329038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NIOSH.1">
<a name="NIOSH.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed August 30, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 134464 Version 33.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
